PoulShot MG-F
Mycoplasma gallisepticum (F strain) live vaccine
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Brand name
- PoulShot
- Payment Terms
- L/C,Others,T/T
- Production method
- Available,OEM
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- animal vaccine, poultry vaccine, poulshot, mg-f
- Category
- Veterinary Medicine
ChoongAng Vaccine Laboratories Co., Ltd.(CAVAC)
South Korea
- Verified Certificate
-
16
| Product name | PoulShot MG-F | Certification | - |
|---|---|---|---|
| Category | Veterinary Medicine | Ingredients | MYCOPLASMA GALLISEPTICUM |
| Keyword | animal vaccine , poultry vaccine , poulshot , mg-f | Unit Size | - |
| Brand name | PoulShot | Unit Weigh | - |
| origin | South Korea | Stock | 0 |
| Supply type | Available,OEM | HS code | 300230 |
Product Information
F strain for MG live vaccine for poultry
PoulShot® MG-F
Indication
An aid in the control and prevention of avian mycoplasmosis caused by Mycoplasma gallisepticum
in chickens.
Composition and quantity (per dose)
Mycoplasma gallisepticum (F810 strain) …………………..≥1ⅹ105CCU
Stabilizer ……………………………………………………….q.s.
Features
F strain with the proven effectiveness worldwide forms colonization in the respiratory
tract for a long time to exclude the field MG strain competitively.
The effect lasts long after inoculation and reinfection of pathogenic MG strain is prevented.
Long-lasting high level of antibody formation.
Easy storage and handling due to cold storage.
Administration and dosage
Reconstitute the vaccine with the enclosed diluent
and administer one eye drop (0.03㎖).
1st vaccination: 6 weeks of age
2nd vaccination: 3 weeks after first vaccination
Vaccination against Newcastle disease, infectious bronchitis, and fowl Pox is not
recommended 4 weeks before and after vaccination.
It does not apply to inactivated vaccine.
Packaging unit
1,000 doses/vial
B2B Trade
| Price (FOB) | Negotiable | transportation | Air Transportation,Negotiation Other,Ocean Shipping |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | L/C,Others,T/T | Shipping time | Negotiable |
- President
- Injoong Yoon
- Address
- 1476-37 Yuseong-daero, Yuseong-gu, Daejeon, Korea
- Product Category
- Veterinary Medicine
- Year Established
- 1968
- No. of Total Employees
- 101-500
- Company introduction
-
As an innovative animal vaccine company, CAVAC’s long journey with continuing efforts
CAVAC leads the way in animal health
CAVAC is a powerful leader in the field of animal biological products. We provide a wide range of groundbreaking pharmaceutical products that promote animal health and welfare, as well as improving the quality of life of people in Korea.
CAVAC’s long history and continued efforts
Since it was founded in 1968, CAVAC has grown to become renowned in Korea as a developer and manufacturer of animal vaccines. With over 80 animal vaccine products, the company is a key player in the Korean and global markets. We have achieved multiple vendor audits conducted by multinational companies and government audits. CAVAC is also committed to finding better solutions for pharmaceutical, biological and diagnostic products, and strives to be a pioneering partner offering a wide range of services.
Global bio leader in the advanced animal vaccine industry
As an animal vaccine company, CAVAC has experienced accelerated growth. As well as enhancing the development of new products and technologies, we have maximized our investments to protect against challenges and competition from various global companies. CAVAC is strategically located in the Daedeok Innopolis, also known as the Silicon Valley of Korea, and has teamed up with a number of prominent research institutions. CAVAC is now expanding onto the global market and is striving to become one of the top 10 global partners in animal health.
- Main Markets
-
Bangladesh
Cambodia
Indonesia
Myanmar
Nepal
Pakistan
Philippines
Thailand
Viet Nam
- Factory Information
-
(주)중앙백신연구소,
주식회사 중앙백신연구소
- Main Product
